CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN

Simple item page
dc.contributor.authorCiruelos, E.
dc.contributor.authorAlba, E.
dc.contributor.authorLopez, R.
dc.contributor.authorLluch, A.
dc.contributor.authorMartin, M.
dc.contributor.authorArroyo, I
dc.contributor.authorNavarro, B.
dc.contributor.authorCarcedo, D.
dc.contributor.authorColomer, R.
dc.contributor.authorAlbanell, J.
dc.contributor.authoraffiliation[Ciruelos, E.] Hosp Univ 12 Octubre, Ctr Oncol Clara Campal, Med Oncol Serv, Madrid, Spain
dc.contributor.authoraffiliation[Alba, E.] Hosp Univ Reg, Clin Oncol Unit, Malaga, Spain
dc.contributor.authoraffiliation[Alba, E.] Hosp Univ Virgen de la Victoria, Clin Oncol Unit, Malaga, Spain
dc.contributor.authoraffiliation[Alba, E.] Inst Invest Bioed Malaga IBIMA, Malaga, Spain
dc.contributor.authoraffiliation[Lopez, R.] Hosp Clin Univ, Med Oncol Dept, Santiago De Compostela, La Coruna, Spain
dc.contributor.authoraffiliation[Lopez, R.] Inst Invest Santiago CIBERONC, Santiago De Compostela, La Coruna, Spain
dc.contributor.authoraffiliation[Lluch, A.] Univ Valencia, Ctr Networked Biomed Canc Res CIBERONC, Hlth Res Inst INCLIVA, Hosp Clin Univ Valencia,Med Oncol Serv, Valencia, Spain
dc.contributor.authoraffiliation[Martin, M.] Univ Complutense, Med Oncol Serv, Inst Invest Sanitaria Gregorio Maranon, GEICAM,CIBERONC, Madrid, Spain
dc.contributor.authoraffiliation[Arroyo, I] Roche Farma, Payer Evidence & Hlth Econ Unit, Madrid, Spain
dc.contributor.authoraffiliation[Navarro, B.] Roche Pharma, Med Dept, Madrid, Spain
dc.contributor.authoraffiliation[Carcedo, D.] Oblikue Consulting, Barcelona, Spain
dc.contributor.authoraffiliation[Colomer, R.] Hosp Univ La Princesa, Med Oncol Serv, Madrid, Spain
dc.contributor.authoraffiliation[Albanell, J.] Hosp Mar, Med Oncol Serv, Barcelona, Spain
dc.date.accessioned2025-01-07T15:16:00Z
dc.date.available2025-01-07T15:16:00Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jval.2018.09.102
dc.identifier.essn1524-4733
dc.identifier.issn1098-3015
dc.identifier.unpaywallURLhttp://www.valueinhealthjournal.com/article/S1098301518334028/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27001
dc.identifier.wosID459985600082
dc.issue.number3
dc.journal.titleValue in health
dc.journal.titleabbreviationValue health
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS18-S18
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.titleCONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number21
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía